Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone

Yan Zhang1, Xiao-Li Li2, Nan-Nan Sha1

  • 1Spine Disease Research Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.

Bone
|January 29, 2017
PubMed

Insights

Captopril, an angiotensin-converting enzyme inhibitor, improved kidney function in diabetic mice but worsened bone density. This highlights a potential trade-off in treating diabetic complications with this drug.

Area of Science:

  • Endocrinology and Metabolism
  • Nephrology
  • Orthopedics

Background:

  • Diabetes mellitus is frequently associated with kidney disease and bone complications.
  • The renin-angiotensin system (RAS) plays a role in both kidney and bone physiology.
  • Angiotensin-converting enzyme (ACE) inhibitors are used to manage hypertension and diabetic nephropathy.

Purpose of the Study:

  • To investigate the effects of captopril on kidney and bone in a mouse model of type 2 diabetes (db/db mice).
  • To elucidate the molecular mechanisms underlying captopril's actions on renal and skeletal tissues.

Main Methods:

  • db/db mice and non-diabetic db/+ mice were treated with captopril or vehicle for 8 weeks.
  • Kidney and bone tissues were analyzed using biochemical assays, histology, microcomputed tomography, qPCR, and immunoblotting.
  • Parameters assessed included renal function markers, bone mineral density, bone microarchitecture, and gene/protein expression related to RAS, fibrosis, and bone metabolism.

Main Results:

  • Captopril significantly ameliorated albuminuria and glomerulosclerosis in db/db mice, linked to reduced angiotensin II and profibrotic factor expression in the kidney.
  • However, captopril treatment led to increased urinary calcium and phosphorus excretion, decreased bone mineral density, and deteriorated tibial trabecular bone structure.
  • Molecular analysis revealed captopril's impact on bone metabolism, including increased osteoclast activity and decreased osteoblast function markers.

Conclusions:

  • Captopril demonstrates therapeutic benefits for diabetic kidney injury by modulating the intrarenal RAS.
  • Conversely, captopril treatment negatively impacts bone health in diabetic mice, potentially by promoting osteoclastogenesis and inhibiting osteogenesis.
  • These findings suggest a complex interplay between RAS inhibition, renal protection, and bone metabolism in diabetes.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K